Trial Profile
A Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis With Clinical Remission or Response From Induction Therapy. (NATRUL-4)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs HMPL 004 (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms NATRUL-4
- Sponsors Hutchison MediPharma
- 05 May 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 22 Jul 2013 New trial record
- 17 Jul 2013 Status changed from not yet recruiting to recruiting based on information reported in a Nutrition Science Partners media release. The first patient has been treated.